Cancer Research and Treatment

Li Zhu

3 Articles

Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study: Jiayi Wu, Shuning Ding, Lin Lin, Xiaochun Fei, Caijin Lin, Lisa Andriani, Chihwan Goh, Jiahui Huang, Jin Hong, Weiqi Gao, Siji Zhu, Hui Wang, Ou Huang, Xiaosong Chen, Jianrong He, Yafen Li, Kunwei Shen, Weiguo Chen, Li Zhu; Cancer Res Treat. 2020;52(3):671-679. Published online January 28, 2020; DOI: https://doi.org/10.4143/crt.2019.387

Purpose
This retrospective study aimed to evaluate the distribution pattern and prognostic value of 21-gene recurrence score (RS) in Chinese patients with mucinous breast cancer (MC) and compared with infiltrating ductal carcinoma (IDC).
Materials and Methods
Patients diagnosed with MC or IDC from January 2010 to January 2017 were retrospectively recruited. Reverse transcriptase–polymerase chain reaction assay of 21 genes was conducted to calculate the RS. Univariate and multivariate analyses were performed to assess the association between RS and clinicopathological factors. Survival outcomes including disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared by log-rank test.
Results
The MC cohort included 128 patients and the IDC cohort included 707 patients. The proportions of patients with a low (RS < 18), intermediate (18-30), or high risk (RS > 30) were 32.0%, 48.4%, and 19.5% in MC cohort, and 26.9%, 46.8% and 26.3% in IDC cohort. The distribution of RS varied significantly according to different Ki-67 index and molecular subtype in both cohorts. Moreover, the receipt of chemotherapy was associated with RS in both cohorts. Among patients with MC, tumor stage was related to the DFS (p=0.040). No significant differences in DFS and OS were found among MC patients in different RS risk groups (OS, p=0.695; DFS, p=0.926).
Conclusion
RS was significantly related to Ki-67 index and molecular subtypes in MC patients, which is similar in IDC patients. However, RS was not able to predict DFS and OS in patients with MC.

Citations

Citations to this article as recorded by

Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer
Qianyi Lu, Hanxing Zhou, Jianwei Zhang, Kaping Lee, Limin Chen, Ruoxi Hong, Kuikui Jiang, Fei Xu, Wen Xia, Boyang Cao, Jingmin Zhang, Kang Shao, Peng Sun, Shusen Wang
The Breast.2024; 76: 103760. CrossRef
A clinicopathologic analysis of 70 patients with mucinous breast carcinoma
Rupali Sood, Karin Miller, Hua-Ling Tsai, Ashley Cimino-Mathews, Roisin M. Connolly
Current Problems in Cancer: Case Reports.2024; 15: 100304. CrossRef
Clinicopathological features and prognosis of mucinous breast carcinoma with a micropapillary structure
Beibei Yang, Menglu Shen, Bo Sun, Jing Zhao, Meng Wang
Thoracic Cancer.2024;[Epub] CrossRef
Distribution, Chemotherapy Use, and Outcome of the 21-Gene Recurrence Score Between Chinese and White breast Cancer in the United States
Guan-Qiao Li, Jia Yao, Ping Zhou, Dan-Xia Chen, Chen-Lu Lian, Shi-Ping Yang, Cai-Hong Huang, San-Gang Wu
Clinical Breast Cancer.2022; 22(3): 279. CrossRef
Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients
Yiwei Tong, Jiahui Huang, Weili Ren, Jing Yu, Xu Zhang, Zheng Wang, Jin Hong, Weiqi Gao, Jiayi Wu, Min Ji, Kunwei Shen, Xiaosong Chen
European Journal of Medical Research.2022;[Epub] CrossRef
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients
Peng Qi, Yu Yang, Qian-ming Bai, Tian Xue, Min Ren, Qian-lan Yao, Wen-tao Yang, Xiao-yan Zhou
Breast Cancer Research and Treatment.2021; 186(2): 327. CrossRef
Oncotype DX 21‑gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
Rui Chen, Yun Wang, Taolang Li, Junyuan Lv, Guoli Feng, Na Tan, Jinjing Wang, Xiaoming Cheng
Oncology Letters.2021;[Epub] CrossRef

7,464 View
162 Download
7 Web of Science
7 Crossref

Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score–Adjusted, Population-Based Study: Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Kunwei Shen, Li Zhu; Cancer Res Treat. 2020;52(2):552-562. Published online November 18, 2019; DOI: https://doi.org/10.4143/crt.2019.210

Abstract PDF Supplementary Material PubReader ePub

Purpose
Despite the rapid growing of cancer survivors, prior cancer history is a commonly adopted exclusion criterion. Whether prior cancer will impact the survival of patients with advanced breast cancer (ABC) remains uncertain.
Materials and Methods
Patients with ABC diagnosed between 2004 and 2010 were identified using Surveillance, Epidemiology, and End Results (SEER) database. Timing, stage, and type were used to characterize prior cancer. Multivariable analyses using propensity score–adjusted Cox regression and competing risk regression were conducted to evaluate the prognostic effect of prior cancer on overall survival (OS) and breast cancer-specific survival (BCSS).
Results
A total of 14,176 ABC patients were identified, of whom 10.5% carried a prior cancer history. The most common type of prior cancer was female genital cancer (32.4%); more than half (51.7%) were diagnosed at localized stage; most were diagnosed more than 5 years (42.9%) or less than 1 year (28.3%) prior to the index cancer. In multivariate analyses, patients with prior cancer presented a slightly worse OS (hazard ratio, 1.18; 95% confidence interval [CI], 1.07 to 1.30; p=0.001) but a better BCSS (subdistribution hazard ratio, 0.64; 95% CI, 0.56 to 0.74; p < 0.001). In subset analyses, no survival detriment was observed in patients with prior malignancy from head and neck or endocrine system, at in situ or localized stage, or diagnosed more than 4 years.
Conclusion
Prior cancer provides an inferior OS but a superior BCSS for patients with ABC. It does not affect the survival adversely in some subgroups and these patients should not be excluded from clinical trials.

Citations

Citations to this article as recorded by

Impact of childhood/adolescent cancer history on prognosis in parotid mucoepidermoid carcinoma
Hefeng Gu, Sunyi Tu, Lan Ma, Kuiwei Su, Yeqing Zhou
British Journal of Oral and Maxillofacial Surgery.2024; 62(7): 612. CrossRef
Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer
Chaojie Xu, Dongchen Pei, Yi Liu, Jianhua Guo, Nan Liu, Qian Wang, Yang Yu, Zhengjun Kang
Frontiers in Oncology.2023;[Epub] CrossRef
The Impact of a History of Different Other Cancers on the Long-Term Outcomes of Patients with Gallbladder Cancer: A Propensity Score–Adjusted, Population-Based Study
Jing Wang, Chan Zhang, Dong Yan
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Second primary malignancies in oral tongue cancer: A Surveillance, Epidemiology, and End Result–based analysis evaluating the basic characteristics, survival outcomes, and predictive factors
Zicheng Xu, Jianxing Wang, Hongzhou Cai, Feng Qi, Qing Zou
Precision Medical Sciences.2022; 11(1): 4. CrossRef
Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study
Jiayue Ye, Sheng Hu, Wenxiong Zhang, Deyuan Zhang, Yang Zhang, Dongliang Yu, Jinhua Peng, Jianjun Xu, Yiping Wei
Frontiers in Surgery.2022;[Epub] CrossRef
Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer
Weixun Lin, Yaokun Chen, Zeqi Ji, Lingzhi Chen, Jinyao Wu, Yexi Chen, Zhiyang Li, Nauman Rahim Khan
BioMed Research International.2022; 2022: 1. CrossRef
Association between a prior cancer history and prognosis in adult patients with high‑grade glioma
Dongjie He, Peiwen Wu, Gaiyan Li, Siying Zhu, Qiming Wang, Qiuju Shao, Hao Chang
Journal of Clinical Neuroscience.2022; 106: 20. CrossRef
Impact of prior cancer history on survival of patients with gastric cancer
Li Wen, Kun Yu, Hongjiang Lu, Guansheng Zhong
European Journal of Surgical Oncology.2021; 47(9): 2286. CrossRef
Effect of prior cancer on survival outcomes for patients with advanced prostate cancer
Yechen Wu, Xi Chen, Duocheng Qian, Wei Wang, Yiping Zhang, Jinxin Hu, Jun Zhu, Qiang Wu, Tinghu Cao
BMC Urology.2021;[Epub] CrossRef
Survival of women diagnosed with breast cancer and who have survived a previous cancer
Sandi L. Pruitt, Hong Zhu, Daniel F. Heitjan, Asal Rahimi, Bhumika Maddineni, Anna Tavakkoli, Ethan A. Halm, David E. Gerber, Danyi Xiong, Caitlin C. Murphy
Breast Cancer Research and Treatment.2021; 187(3): 853. CrossRef
Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers
Chelsea Anderson, Deborah K. Mayer, Hazel B. Nichols
Cancer.2021; 127(15): 2736. CrossRef
Survival analysis of patients with primary breast duct carcinoma and lung adenocarcinoma: a population-based study from SEER
Fengyuan Lv, Mingliang Cheng, Liang Jiang, Xiaoping Zhao
Scientific Reports.2021;[Epub] CrossRef
Research on Effectiveness of Prior Cancer on Survival Outcomes for Patients with Nonmetastatic Triple-Negative Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of the SEER Database
Heyan Chen, Lutong Yan, Shengyu Pu, Lizhe Zhu, Huimin Zhang, Can Zhou, Raffaele Palmirotta
Journal of Oncology.2021; 2021: 1. CrossRef
Risk of breast cancer-related death in women with a prior cancer
Fei Ji, Ci-Qiu Yang, Xiao-Ling Li, Liu-Lu Zhang, Mei Yang, Jie-Qing Li, Hong-Fei Gao, Teng Zhu, Min-Yi Cheng, Wei-Ping Li, Si-Yan Wu, Ai-Ling Zhong, Kun Wang
Aging.2020; 12(7): 5894. CrossRef

7,922 View
178 Download
17 Web of Science
14 Crossref

Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study: Jiahui Huang, Xiaosong Chen, Xiaochun Fei, Ou Huang, Jiayi Wu, Li Zhu, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen; Cancer Res Treat. 2019;51(4):1336-1346. Published online February 12, 2019; DOI: https://doi.org/10.4143/crt.2018.504

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the changes of tumor infiltrating lymphocytes (TILs) between core needle biopsy (CNB) and surgery removed sample (SRS) in early stage breast cancer patients and to identify the correlating factors and prognostic significance of TILs changes.
Materials and Methods
A retrospective study was carried out on 255 patients who received CNB and underwent surgical resection for invasive breast cancer. Stromal TILs levels of CNB and SRS were evaluated respectively. Tumors with ≥50% stromal TILs were defined as lymphocyte-predominant breast cancer (LPBC). Clinicopathological variables were analyzed to determine whether there were factors associated with TILs changes. Log-rank tests and Cox proportional hazards models were used to analyze the influences of TILs and TILs changes on survival.
Results
SRS-TILs (median, 10.0%) were significant higher than CNB-TILs (median, 5.0%; p<0.001). Younger age (<60 years, p=0.016) and long surgery time interval (STI, ≥4 days; p=0.003) were independent factors correlating with higher TILs changes. CNB-LPBC patients showed better breast cancer-free interval (BCFI, p=0.021) than CNB-non-LPBC (CNB-nLPBC) patients. Patients were categorized into four groups according to the LPBC change pattern from CNB to SRS: LPBC→LPBC, LPBC→nLPBC, nLPBC→LPBC, and nLPBC→nLPBC, with estimated 5-year BCFI 100%, 100%, 69.7%, and 86.0% (p=0.016). nLPBC→LPBC pattern was an independent prognostic factor of worse BCFI (hazard ratio, 2.19; 95% confidence interval, 1.06 to 4.53; p=0.035) compared with other patterns.
Conclusion
TILs were significantly higher in SRS than in CNB. Higher TILs changes were associated with younger age and long STI. Changing from nLPBC to LPBC after CNB indicated a worse BCFI, which needs further validation.

Citations

Citations to this article as recorded by

A nomogram to predict the pathological complete response in patients with breast cancer based on the TILs-US score
Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Koji Arihiro, Morihito Okada
Japanese Journal of Clinical Oncology.2024; 54(9): 967. CrossRef
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Anne Monette, Sarah Warren, J Carl Barrett, Charlie Garnett-Benson, Kurt A Schalper, Janis M Taube, Brian Topp, Alexandra Snyder
Journal for ImmunoTherapy of Cancer.2024; 12(7): e009427. CrossRef
Diagnostic performance of TILs–US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer
Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Erika Yokoyama, Makiko Tanaka, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Tetsuya Nakagiri, Koji Arihiro, Morihito Okada
International Journal of Clinical Oncology.2024;[Epub] CrossRef
Stromal grading predicts pathologic complete response and prognosis in triple-negative breast cancer
Sean M. Hacking, Yihong Wang
Virchows Archiv.2023; 483(6): 765. CrossRef
Whole slide image features predict pathologic complete response and poor clinical outcomes in triple-negative breast cancer
Sean M. Hacking, Julie Karam, Kamaljeet Singh, Ece D. Gamsiz Uzun, Arlen Brickman, Evgeny Yakirevich, Ross Taliano, Yihong Wang
Pathology - Research and Practice.2023; 246: 154476. CrossRef
Tumor infiltrating lymphocytes and radiological picture of the tumor
Karolina Frankowska, Michał Zarobkiewicz, Izabela Dąbrowska, Agnieszka Bojarska-Junak
Medical Oncology.2023;[Epub] CrossRef
Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma
Minna Mutka, Kristiina Joensuu, Marja Heiskala, Mine Eray, Päivi Heikkilä
Virchows Archiv.2023; 483(2): 215. CrossRef
Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
Yujie Lu, Yiwei Tong, Xiaochun Fei, Xiaosong Chen, Kunwei Shen
Cancer Medicine.2023; 12(15): 16264. CrossRef
Time interval between breast cancer diagnosis and surgery is associated with disease outcome
Siji Zhu, Shuai Li, Jiahui Huang, Xiaochun Fei, Kunwei Shen, Xiaosong Chen
Scientific Reports.2023;[Epub] CrossRef
Evaluation of tumor-infiltrating lymphocytes and mammographic density as predictors of response to neoadjuvant systemic therapy in breast cancer
Amalia H. Landén, Kian Chin, Anikó Kovács, Erik Holmberg, Eva Molnar, Axel Stenmark Tullberg, Fredrik Wärnberg, Per Karlsson
Acta Oncologica.2023; 62(12): 1862. CrossRef
Magnetic Resonance Imaging Features Associated with a High and Low Expression of Tumor-Infiltrating Lymphocytes: A Stratified Analysis According to Molecular Subtypes
Jiejie Zhou, Yi Jin, Haiwei Miao, Shanshan Lu, Xinmiao Liu, Yun He, Huiru Liu, Youfan Zhao, Yang Zhang, Yan-Lin Liu, Zhifang Pan, Jeon-Hor Chen, Meihao Wang, Min-Ying Su
Cancers.2023; 15(23): 5672. CrossRef
Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer
Giuseppe Angelico, Giuseppe Broggi, Rosario Caltabiano, Angela Santoro, Saveria Spadola, Nicoletta D’Alessandris, Giulia Scaglione, Michele Valente, Damiano Arciuolo, Alejandro Martin Sanchez, Gianluca Franceschini, Riccardo Masetti, Antonino Mulè, Gian F
Applied Sciences.2021; 11(15): 6788. CrossRef
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Zuzana Kos, Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen, Koen K. van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, W. Fraser Symmans, Christos Sotiriou, David L. Rimm
npj Breast Cancer.2020;[Epub] CrossRef
Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?
Alexandra Caziuc, Diana Schlanger, Giorgiana Amarinei, George Calin Dindelegan
Journal of Clinical Medicine.2019; 8(4): 545. CrossRef

6,969 View
212 Download
16 Web of Science
14 Crossref

Author index